The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BBIO | +138.79% | +56.95% | +9.42% | +124% |
| S&P | +12.65% | +91.73% | +13.89% | +130% |
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Upcoming Food and Drug Administration decisions could push these stocks through the roof.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $120.70M | 4318.0% |
| Gross Profit | $113.44M | 12560.6% |
| Gross Margin | 93.98% | 61.2% |
| Market Cap | $9.93B | 107.4% |
| Market Cap / Employee | $13.60M | 0.0% |
| Employees | 730 | 32.7% |
| Net Income | -$184.94M | -12.6% |
| EBITDA | -$134.96M | 27.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $643.08M | 58.5% |
| Accounts Receivable | $116.52M | 24276.2% |
| Inventory | 24.5 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.69B | 56.0% |
| Short Term Debt | $13.90M | 202.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -95.85% | -29.4% |
| Return On Invested Capital | -98.51% | -4.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$110.04M | 39.1% |
| Operating Free Cash Flow | -$109.57M | 39.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -4.22 | -4.48 | -4.97 | -5.55 | 26.79% |
| Price to Sales | 23.43 | 51.59 | 34.89 | 28.17 | 27.80% |
| Price to Tangible Book Value | -4.13 | -4.40 | -4.89 | -5.46 | 27.60% |
| Enterprise Value to EBITDA | -30.63 | -81.93 | -76.85 | -89.16 | 169.73% |
| Total Debt | $2.21B | $2.36B | $2.68B | $2.70B | 56.35% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
